- $40.26bn
- $32.23bn
- $6.85bn
- 73
- 22
- 71
- 55
Annual income statement for Moderna, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 60.2 | 803 | 18,471 | 19,263 | 6,848 |
| Cost of Revenue | |||||
| Gross Profit | — | 795 | 15,854 | 13,847 | 2,155 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 606 | 1,567 | 5,175 | 9,843 | 11,087 |
| Operating Profit | -546 | -763 | 13,296 | 9,420 | -4,239 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -515 | -745 | 13,285 | 9,575 | -3,942 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -514 | -747 | 12,202 | 8,362 | -4,714 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -514 | -747 | 12,202 | 8,362 | -4,714 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -514 | -747 | 12,202 | 8,362 | -4,714 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.55 | -1.96 | 28.3 | 20.1 | -12.3 |